- Keywords > access to medicines
- Keywords > affordability
- Keywords > availability
- Keywords > equity
- Keywords > price comparison
- Keywords > price of treatment
- Keywords > prices / pricing policy
- Keywords > pricing methodology
- Keywords > reproductive health
- Keywords > reproductive health medicines
- Keywords > WHO/HAI methodology
(2006; 29 pages)
Product price may be one barrier to access, putting medicines out of the reach of large population segments. Rigorous, or even cursory, price data for reproductive health medicines and commodities within and across countries are generally unavailable, and what data are known from individual countries are not widely disseminated. The World Health Organization (WHO) and Health Action International (HAI) developed a methodology to obtain price information for essential medicines through a systematic approach that involves onsite collection of retail prices of common medicines from a sample of public, private, or other sector dispensaries in a country. The methodology, which is described in the workbook, Medicine Prices: A New Approach to Measurement, was designed to be a low-cost, reliable way to help meet the need for greater transparency on prices in the international medicines marketplace.
In 2005, PATH and John Snow International (JSI)/DELIVER collaborated to conduct pilot reproductive health commodity price measurement studies in two developing countries using this methodology. PATH and JSI/DELIVER felt that the WHO/HAI approach would be valuable in providing a pricing context for reproductive health medicines and worked on developing a list of essential reproductive health medicines that could serve as indicators for pricing and accessibility. PATH conducted a study of reproductive health commodity prices in Nicaragua while JSI/DELIVER conducted a similar survey in Nepal. These studies aimed to gain an understanding of how prices and price components of reproductive health commodities affect the end user’s ability to access these reproductive health medicines and how this affects access, affordability, and equity for all population segments. If essential reproductive health medicines are available, affordable, of good quality, and properly used, they can significantly improve reproductive health...